Total item
Cart Subtotal
$0.00 Biological Activity
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation.
Targets
| Target | Value |
|---|---|
| CDK9/CyclinT | IC50: <10nM |
| CDK5/p35 | IC50: 13nM |
| CDK2/CyclinA | IC50: 47nM |
| GSK-3β | IC50: 89nM |
| CDK4/CyclinD1 | IC50: 100nM |
| CDK6/CyclinD3 | IC50: 170nM |
| CDK1/CyclinB | IC50: 210nM |
| CDK3/CyclinE | IC50: 360nM |
| PI3Kβ | IC50: >1μM |
| PLK3 | IC50: >1μM |
| RET | IC50: >1μM |
| SGK | IC50: >1μM |
| TrkB | IC50: >1μM |
| JAK2 | IC50: >1μM |
| CDK7/CyclinH/MAT1 | IC50: 2.4μM |
| SAPK2A(p38α) | IC50: >10μM |
| p70S6K | IC50: >10μM |
| PDGFR | IC50: >10μM |
| PDK-1 | IC50: >10μM |
| PKBβ | IC50: >10μM |
| VEGFR1 | IC50: >10μM |
| AuroraA | IC50: >10μM |
| c-Abl | IC50: >10μM |
| c-Src | IC50: >10μM |
| Chk1 | IC50: >10μM |
| EGFR | IC50: >10μM |
| FGFR3 | IC50: >10μM |
| IR | IC50: >10μM |
| JNK2 | IC50: >10μM |
| MAPK1 | IC50: >10μM |
| MEK1 | IC50: >10μM |
| Met | IC50: >10μM |
| In vitro (25°C) | DMSO | 10 mg/mL (26.16 mM) | |
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 30% propylene glycol, 5% Tween 80, 65% D5W | 30 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 26.16 mL | 130.82 mL | 261.64 mL |
| 0.5 mM | 5.23 mL | 26.16 mL | 52.33 mL |
| 1 mM | 2.62 mL | 13.08 mL | 26.16 mL |
| 5 mM | 0.52 mL | 2.62 mL | 5.23 mL |
*The above data is based on the productmolecular weight 382.2. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A10093 |
|---|---|
| Actions | Inhibitor |
| M. Wt | 382.2 |
| Formula | C16H17Cl2N5O2 |
| Solubility | DMSO |
| Purity | >98% |
| Storage | at -20°C 3 years Powder |
| CAS No. | 844442-38-2 |
| Synonyms | AT-7519 |
| SMILES | C1CNCCC1NC(=O)C2=C(C=NN2)NC(=O)C3=C(C=CC=C3Cl)Cl |
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
PD 0332991 HCl (Palbociclib)
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activit…
AT7519 HCl
AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhib…
NVP-LCQ195
NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.
Flavopiridol HCl
Flavopiridol HCl is an inhibitor of cyclin-dependent kinases. The (-)-cis form induces apoptosis in particular tumor cells.
P276-00
P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. In Phase 2/3
Dinaciclib (SCH 727965)
Dinaciclib (SCH 727965) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, selectively inhibiting CDK1, CDK2, CDK5 and CDK9 …
CVT-313
CVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 2…
PHA-793887
PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity ag…
Keywords:buy AT7519 | AT7519 Supplier | purchase AT7519 | AT7519 cost | AT7519 manufacturer | order AT7519 | AT7519 distributor | buy 844442-38-2| 844442-38-2 Supplier | purchase 844442-38-2 | 844442-38-2 cost | 844442-38-2 manufacturer | order 844442-38-2 | 844442-38-2 distributor
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: [email protected]
Not your Region? View all Distributors
Adooq Quality Guarantee
We promise all products perform as described.